Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 43Sarcoma 7Genitourinary 3Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
eribulin × Gastrointestinal × 1 year × Clear all
NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Enliven Therapeutics

Phase 1 Active not recruiting
275 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡